Wanbang Biopharmaceuticals Co., Ltd.
Industry
- Pharmaceuticals
- Biotechnology
See more in Biomedtracker
Latest on Wanbang Biopharmaceuticals Co., Ltd.
Scrip
• By Anju Ghangurde, Joseph Haas, Ian Haydock, Jung Won Shin, Lisa Takagi, Dexter Jie Yan, and Brian Yang
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Biocytogen Licenses Antibodies For
Scrip
• By Dexter Jie Yan
On 29 November, Shanghai-based Full-Life Technologies Limited announced it would acquire Focus-X Therapeutics, a two-year-old US biotech focusing on the development of peptide receptor radionuclide